India has so far reported approximately cases of 8,848 mucormycosis or black fungus, one of the rapidly spreading infections observed in those recovering from Covid-19.
Taking note of the increasing numbers, the Central government has emphasised upon expediting the allocation of vials of Amphotericin-B, a key drug to treat raging mucormycosis.
In this direction, the Union minister of chemicals and fertilisers D.V. Sadananda Gowda has announced an allocation of 23,680 additional vials of Amphotericin-B.
The minister also informed that the allocation has been made based on total number of patients which is approximately 8,848 across the country.
Gujarat (5,800) and Maharashtra (5,090) have been allocated the maximum number of the additional Amphotericin-B vials followed by Andhra Pradesh (2,310), Madhya Pradesh (1,830), Rajasthan (1,780), Karnataka (1,270).
Gujarat has reported maximum of 2,281 mucormycosis cases followed by Maharashtra (2,000), Andhra Pradesh (910), Madhya Pradesh (720) Rajasthan (700), Karnataka (5,00), Haryana (250), Delhi (197), Punjab (95), Chhattisgarh (87), Bihar (56), Tamil Nadu (40), Kerala (36), Jharkhand (27), Odisha (15), Goa (12) and Chandigarh (8).
Mucormycosis is a serious but rare fungal infection caused by a group of molds called mucormycetes that has been developing in Covid-19 patients. The fungal disease is commonly being observed in patients who were given steroids for a long time, who have been hospitalised for a long time, were on oxygen support or ventilator, faced poor hospital hygiene or those who have been taking medication for other illnesses such as diabetes. If not treated on time, the black fungus infection can turn fatal. The Covid medications can leave the body weak and low on immunity. They can also escalate the blood sugar levels in both diabetics and non-diabetic Covid-19 patients.
–IANS
rak/ash
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
Source link
